Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma? (Q55457286)

11 July 2018

title

Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma? (English)

1 reference

11 July 2018

1 reference

2

Patrick Y Wen

1 reference

11 July 2018

author name string

Sylvia C Kurz

series ordinal

1

1 reference

11 July 2018

publication date

18 April 2018

1 reference

11 July 2018

Current treatment options in neurology

published in

1 reference

11 July 2018

volume

20

1 reference

11 July 2018

issue

5

1 reference

11 July 2018

page(s)

14

1 reference

11 July 2018

Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors

cites work

1 reference

12 December 2020

Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia

1 reference

12 December 2020

Structural alterations of the epidermal growth factor receptor gene in human gliomas

1 reference

12 December 2020

Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation

1 reference

12 December 2020

Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro

1 reference

12 December 2020

Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas

1 reference

12 December 2020

Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response

1 reference

12 December 2020

T cell adoptive immunotherapy of newly diagnosed gliomas

1 reference

12 December 2020

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

1 reference

12 December 2020

Telomerase as a therapeutic target for malignant gliomas.

1 reference

12 December 2020

T cell apoptosis by tryptophan catabolism

1 reference

12 December 2020

Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas.

1 reference

12 December 2020

Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors

1 reference

12 December 2020

Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis

1 reference

12 December 2020

Antigen-specific inhibition of CD8 T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

1 reference

12 December 2020

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

1 reference

12 December 2020

Role of LAG-3 in regulatory T cells.

1 reference

12 December 2020

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

1 reference

12 December 2020

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

1 reference

12 December 2020

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results

1 reference

12 December 2020

B7-homolog 1 expression by human glioma: a new mechanism of immune evasion.

1 reference

12 December 2020

HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo

1 reference

12 December 2020

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

1 reference

12 December 2020

Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.

1 reference

12 December 2020

Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1

1 reference

12 December 2020

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

1 reference

12 December 2020

IL-2 regulates FOXP3 expression in human CD4 CD25 regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo

1 reference

12 December 2020

CD4 CD25 FoxP3 T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas

1 reference

12 December 2020

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment

1 reference

12 December 2020

Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1.

1 reference

12 December 2020

Expression of EphA2 in human astrocytic tumors: correlation with pathologic grade, proliferation and apoptosis

1 reference

12 December 2020

Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy

1 reference

12 December 2020

WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?

1 reference

12 December 2020

Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.

1 reference

12 December 2020

A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.

1 reference

12 December 2020

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study

1 reference

12 December 2020

Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.

1 reference

12 December 2020

A phase I trial of Ad.hIFN-beta gene therapy for glioma

1 reference

12 December 2020

A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy

1 reference

12 December 2020

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

1 reference

12 December 2020

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

1 reference

12 December 2020

Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

1 reference

12 December 2020

Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells

1 reference

12 December 2020

Incidence and prognostic impact of FoxP3 regulatory T cells in human gliomas.

1 reference

12 December 2020

CTLA-4 control over Foxp3 regulatory T cell function

1 reference

12 December 2020

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.

1 reference

12 December 2020

Neural stem/progenitor cells modulate immune responses by suppressing T lymphocytes with nitric oxide and prostaglandin E2.

1 reference

12 December 2020

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

12 December 2020

IDH1 and IDH2 mutations in gliomas

1 reference

12 December 2020

Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice.

1 reference

12 December 2020

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway

1 reference

12 December 2020

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.

1 reference

12 December 2020

Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors

1 reference

12 December 2020

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

1 reference

12 December 2020

Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines

1 reference

12 December 2020

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

1 reference

12 December 2020

Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway

1 reference

12 December 2020

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors

1 reference

12 December 2020

Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4 T cells.

1 reference

12 December 2020

Prognostic significance and mechanism of Treg infiltration in human brain tumors.

1 reference

12 December 2020

Glioma cancer stem cells induce immunosuppressive macrophages/microglia

1 reference

12 December 2020

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

1 reference

12 December 2020

The detection of CMV pp65 and IE1 in glioblastoma multiforme

1 reference

12 December 2020

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

1 reference

12 December 2020

Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma.

1 reference

12 December 2020

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

1 reference

12 December 2020

MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.

1 reference

12 December 2020

Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma

1 reference

12 December 2020

1 reference

12 December 2020

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

12 December 2020

Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3.

1 reference

12 December 2020

The PD‐1/PD‐L1 (B7‐H1) Pathway in Chronic Infection‐Induced Cytotoxic T Lymphocyte Exhaustion

1 reference

12 December 2020

Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling

1 reference

12 December 2020

Consensus on the role of human cytomegalovirus in glioblastoma

1 reference

12 December 2020

STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells

1 reference

12 December 2020

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma

1 reference

12 December 2020

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

1 reference

12 December 2020

Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein

1 reference

12 December 2020

IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival

1 reference

12 December 2020

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells

1 reference

12 December 2020

Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma

1 reference

12 December 2020

T cells redirected to EphA2 for the immunotherapy of glioblastoma

1 reference

12 December 2020

Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study

1 reference

12 December 2020

Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas

1 reference

12 December 2020

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

12 December 2020

Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages

1 reference

12 December 2020

The roles of TGFβ in the tumour microenvironment

1 reference

12 December 2020

The prognostic value of Foxp3 tumor-infiltrating lymphocytes in patients with glioblastoma

1 reference

12 December 2020

Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial

1 reference

12 December 2020

Genetically modified T cells to target glioblastoma

1 reference

12 December 2020

Tim-3 on peripheral CD4⁺ and CD8⁺ T cells is involved in the development of glioma

1 reference

12 December 2020

Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients.

1 reference

12 December 2020

The M1 and M2 paradigm of macrophage activation: time for reassessment

1 reference

12 December 2020

Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

1 reference

12 December 2020

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

1 reference

12 December 2020

Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.

1 reference

12 December 2020

Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model

1 reference

12 December 2020

A vaccine targeting mutant IDH1 induces antitumour immunity

1 reference

12 December 2020

Shaping the glioma immune microenvironment through tryptophan metabolism

1 reference

12 December 2020

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

1 reference

12 December 2020

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

1 reference

12 December 2020

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma

1 reference

12 December 2020

Cytomegalovirus in human brain tumors: Role in pathogenesis and potential treatment options

1 reference

12 December 2020

The role of STAT3 in tumor-mediated immune suppression

1 reference

12 December 2020

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

1 reference

12 December 2020

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies

1 reference

12 December 2020

Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis

1 reference

12 December 2020

OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy

1 reference

12 December 2020

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

1 reference

12 December 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

12 December 2020

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

12 December 2020

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

12 December 2020

A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma

1 reference

12 December 2020

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8 T Cells in Patients with Recurrent Glioblastoma.

1 reference

12 December 2020

PD-L1 expression and prognostic impact in glioblastoma

1 reference

12 December 2020

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

1 reference

12 December 2020

Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma.

1 reference

12 December 2020

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

1 reference

12 December 2020

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

1 reference

12 December 2020

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies

1 reference

12 December 2020

A polarizing question: do M1 and M2 microglia exist?

1 reference

12 December 2020

The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.

1 reference

12 December 2020

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

1 reference

12 December 2020

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

1 reference

12 December 2020

An immunogenic personal neoantigen vaccine for patients with melanoma

1 reference

12 December 2020

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

1 reference

12 December 2020

Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade

1 reference

12 December 2020

CDK4/6 inhibition triggers anti-tumour immunity.

1 reference

12 December 2020

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

1 reference

12 December 2020

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma

1 reference

12 December 2020

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

1 reference

12 December 2020

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.

1 reference

12 December 2020

CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.

1 reference

12 December 2020

10.1007/S11940-018-0499-0

Identifiers

DOI

1 reference

11 July 2018

Dimensions Publication ID

1103476961

0 references

1 reference

11 July 2018